Prelude Therapeutics Joins Forces with Merck for Cancer Treatment Trial
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has announced a collaboration with Merck to evaluate a new cancer treatment. The Phase 2 clinical trial will test Prelude’s investigational drug, …
Prelude Therapeutics Joins Forces with Merck for Cancer Treatment Trial Read More